Pharma Capital
EPIC: VNRX
Market: NYSE
52-week High/Low:
Sector: Pharma & Biotech
Market Cap: 0.00M

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

VolitionRx

www.volitionrx.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in VolitionRx

VolitionRx Snapshot

Overview

Our Mission

VolitionRx’s mission is to address the need for non-invasive, accurate, and cost-effective diagnostics for cancer and other conditions, with our NuQ® suite of products.

 

About VolitionRx

VolitionRx was established in 2010, when our team of scientists saw a chance to bring together the long-established ELISA diagnostic technology with cutting-edge nucleosome detection and analysis techniques. Their aim: to revolutionize the way cancer is diagnosed.

Cancer and some other diseases lead to irregular levels of uniquely structured nucleosomes in the bloodstream. Though a simple test, with less than a drop of blood, we are able to detect those nucleosomes; and by measuring and analyzing them, to establish whether disease is present in the patient. We are now proving the efficacy of our NuQ® tests in a number of clinical trials being carried out worldwide.

Our R&D and clinical trials teams are based in the heart of Europe, at our laboratory in the medieval university town of Namur, Belgium.

VolitionRx Limited has been listed on the NYSE MKT in the United States of America since February 6, 2015, under the symbol VNRX. The stock was previously quoted on the OTC Bulletin Board.

Conditions

 

Overview

VolitionRx is developing a range of tools for the diagnosis of conditions including:

  • Colorectal cancer
  • Other cancers including prostate and lung cancers
  • Inflammatory and other diseases including endometriosis

Colorectal Cancer

VolitionRx is currently assessing the efficacy of NuQ® for the diagnosis of colorectal cancers, in a number of clinical trials in Europe.

“Colorectal cancer” (CRC) is an umbrella term for cancers of the colon, bowel and rectum. It is the third most common cancer in the US, with around 135,000 new diagnoses and 50,000 deaths from the disease each year.

The US Preventative Services Task Force recommends screening from 50 to 75 years. It recommends a combination of different tests:

  • Every year: Fecal Occult Blood Test (FOBT); over three consecutive stool samples
  • Every five years: flexible sigmoidoscopy (a flexible, lighted tube is used to visually examine rectum and part of colon) (every 3 years if taken with FIT)
  • Every 10 years: colonoscopy; often done under general anesthetic

Only 65% of people are up to date with their colorectal cancer screening, for a variety of reasons including the cost of colonoscopy (the average price is around $2500 in the US) and the unpleasantness and preparation needed for both the colonoscopy and fecal tests.

A VolitionRx survey in 2013 found that 96% of respondents would prefer to take a blood-based test than the alternatives.

More information on our current clinical trials for colorectal cancer is available on our Clinical Trials & Collaborations page.

For information on other conditions please click here

 

Technology

Nucleosomics

VolitionRx is developing a range of diagnostic tests for cancer and other conditions, based on its Nucleosomics® technology.

Nucleosomics® is a platform technology to measure and identify signatures of nucleosomes circulating in the blood.

Nucleosomes of disease origin are structurally different (i.e. have different patterns of histone modification, DNA modifications, DNA methylation or certain adducts) from nucleosomes of other cells.

How Nucleosomics® Works

A nucleosome is a section of DNA that is wrapped around a core of proteins.

DNA is compacted as protein complexes in a “beads on a string” structure.

Nucleosome “beads” consist of DNA wrapped around a core of histone proteins.

Each core consists of four pairs of variants of H2A, H2B, H3 and H4 histones.

Histones and DNA are subject to a variety of post translational modifications.

Various proteins interact with nucleosomes to modulate gene expression.

VolitionRx’s Solution

VolitionRx’s tests have shown, in several trials, the ability to distinguish cancer patients from healthy patients and those with other blood nucleosome-elevating conditions, and to distinguish one type of cancer from another (prostate from colorectal cancer).

Dr. Martin C Faulkes - Chairman

Dr. Martin Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States.

From 1979 to 1984, Dr. Faulkes was the Founder, President and CEO for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business; namely sales, finance, recruitment,staff management and project control. He then became Managing Director of System Programming Ltd., a company that provides computer programming for systems in business like airlines, utility companies, banks, and insurance, from 1985 to 1987, where he was responsible for all aspects of the business. Dr. Faulkes founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a director from 1987 to 1998, responsible for controlling the company financially.

From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the Founder and Sole Benefactor of the Dill Faulkes Educational Trust, a UK registered charity, where he is Chairman. He also sits on the Board of the Cambridge 800th Anniversary Campaign in the UK.

Cameron Reynolds MBA - President & Chief Executive Officer

Cameron Reynolds is an experienced entrepreneurial executive, with expertise in mining and biotechnology companies. He has strong experience in the management, structuring and strategic planning of start-up companies and has held positions including CEO, CFO and Non-Executive Director of public and private enterprises.

Mr. Reynolds has returned to his life sciences and biotechnology roots where in 1996 he began working for Integrated Coffee Technologies, a genetically modified coffee company, in a junior management position, where he was responsible for business plan creation, office management, recruitment, and business development. After working for Integrated Coffee Technologies, Mr Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds held that role from 1998 until 2001, and his main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all shareholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment.

From 2004 until 2011, Mr. Reynolds founded and served as Managing Director and Director of Mining House Limited, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on AIM, TSX and US OTC. From 2005 until present, Mr. Reynolds has held a number of board Directorships including Atlantic Mining PLC; Carbon Mining PLC, Magellan Copper and Gold (Carbon Mining and MCG were both became part of Solfotara Mining and Copper Development Corp on AIM, CDC.L after a vend); KAL Energy Inc. (KALG, OTC), Iofina Natural Gas PLC (IOF, AIM); Canyon Copper Corp. (TSX.V: CNC, OTCBB: CNYC), and Hunter Bay Resources (HBY, TSX-V).

Cameron was educated at the University of Western Australia (Bachelor of Commerce and MBA).

Guy Innes ACA - Non-Executive Director

Guy Archibald Innes is a Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales.

Mr. Innes has extensive experience in financing and managing technology companies, which he gained from serving as a non-executive director on the board of companies such as ProBio Inc. from 2000 to 2006, Magellan Copper & Gold Plc. from 2007 to 2010, and Carbon Mining Plc. from 2007 to 2010.

Prior to holding these directorships, Mr. Innes had a long career in banking and private equity, including advisory roles with Baring Brothers & Co. Limited in London and Paris from 1984 to 1995, where he was involved in executing and advising on national and international mergers & acquisitions, but also IPOs and capital raising; Baring Private Equity Partners Limited in London and Singapore from 1995 to 1997, where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Quartz Capital Partners Limited from 1997 to 2000, where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including IPOs, private placements and mergers and acquisitions.

Mr. Innes was educated at the University of Bristol (BSc Geography), and is a Member of the Institute of Chartered Accountants in England and Wales.

Dr. Alan Colman - Non-Executive Director

Dr. Alan Colman recently retired from his position as Executive Director of the Singapore Stem Cell Consortium and a Principal Investigator at the A*STAR Institute of Medical Biology, in Singapore, having recently and concurrently acted as Professor of Regenerative Medicine at King’s College, London, UK. His main interest was the development of human disease models using induced pluripotent stem cells.

Alan Colman obtained a BA degree in Biochemistry in Oxford (1971) and a PhD under John Gurdon, a pioneer of the field of nuclear transfer, at the Laboratory of Molecular Biology in Cambridge, UK (1974).

After a series of academic appointments in Oxford and Warwick Universities, he became Professor of Biochemistry in the University of Birmingham, UK from 1987-1992. The focus of his academic career was the area of eucaryotic protein secretion, with a particular emphasis on the use of frog oocytes and eggs as in vivo test tubes.

From 1987 until March 2002, he was research director of the company PPL Therapeutics in Edinburgh, UK. This company specialized in the production of transgenic livestock that produced human therapeutic proteins in their milk PPL attracted considerable media attention because of their participation, together with the Roslin Institute, in the technique of somatic nuclear transfer. This work led to Dolly, the world’s first sheep cloned from an adult somatic cell (1996), Polly and Molly, the first cloned transgenic livestock (1997), Diana and Cupid, the first livestock with targeted genetic changes (2000), Millie et al., the first cloned pigs (2000) and, finally, Austin and crew, the first homozygous, alpha gal transferase knock out pigs (2003).

From 2002-2007, he was CSO and then CEO for the Singaporean human embryonic stem cell company, ES Cell International.

Dr. Habib Skaff - Non-Executive Director

Dr. Habib Skaff is a synthetic chemist specializing in the area of nanotechnology, as well as founder and CEO of Intezyne Technologies.

Dr. Skaff received a Ph.D. in Polymer Science and Engineering from the University of Massachusetts. His doctoral studies involved the design of organic and polymeric ligands for the encapsulation of semiconductor nanoparticles and modification of the physical, optical, electronic, and assembly properties of the nanoparticles. He possesses a M.S. in Polymer Science and Engineering from the University of Massachusetts and a B.S. degree in Materials Science and Engineering (Honors) from the University of Florida. He has co-authored 11 peer-reviewed scientific papers and is a co-inventor on 18 pending or issued patents in the fields of chemistry, nanotechnology, and biotechnology.

Dr. Skaff co-founded Intezyne Technologies and serves as the company's Chief Executive Officer, President, and Chairman of the Board of Directors. Dr. Skaff also held the position of President and is currently the Chairman of Skaff Corporation of America (Tampa, Florida). Dr. Skaff serves as a member of the Florida High Tech Corridor Council and as an advisor for the USF Center for Entrepreneurship.

For information on the Management Team please click here

VolitionRx
1 Scotts Road
#24-05 Shaw Centre
Singapore 228208

Belgian Volition SA
Rue du Séminaire 20A
Centre Technologique
Namur BE-5000
Belgium

IR Contacts

Investor Relations
VolitionRx

Scott Powell
T: (646) 650-1351
[email protected]
Investor Relations

The Ruth Group
Lee Roth

T: (646) 536-7012
[email protected]
Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
[email protected]
www.vstocktransfer.com

Auditor
Sadler Gibb & Associates, LLC

2455 East Parleys Way
Suite 320
Salt Lake City, UT 84109

Legal Counsel
Stradling Yocca Carlson & Rauth, P.C.

660 Newport Center Drive
Suite 1600
Newport Beach, CA 92660

VolitionRx Timeline

Newswire

VolitionRx appoints new finance head

View All

Market Reports Including VNRX

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.